首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1593530

全球人類微生物組市場規模、佔有率和成長分析：按產品、按疾病、按類型、按最終用戶、按地區 - 產業預測 (2024-2031)

Human Microbiome Market Size, Share, Growth Analysis, By Product (Drugs, Probiotics), By Disease (Infectious Dieases, Gastrointestinal Diseases), By Type, By End User, By Region - Industry Forecast 2024-2031

出版日期: 2024年11月15日 | 出版商:

SkyQuest | 英文 201 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球人類微生物組市場規模價值為8億美元，預計從2023年的10.1億美元成長到2031年的97億美元，在預測期內（2024-2031年）年複合成長率為31.80%。

人類微生物組已成為一個極其重要的研究領域，特別是因為它對呼吸和免疫健康有重要影響。研究表明，腸道微生物組的組成，特別是放線菌、厚壁菌門和擬桿菌門的組成與呼吸問題之間存在相關性，而微生物組的健康在整體免疫中發揮重要作用。例如，微生物組療法的進展開始增強對 SARS-CoV-2 等新興病原體的免疫反應。此外，這場大流行提高了人們對微生物診斷和化學的認知，為微生物群研究和應用創造了一個強勁的市場。據國際糖尿病協會表示，到2045年，20歲至79歲之間的6900萬人將受到糖尿病的影響，即使在大流行後的情況下，這種趨勢也可能會持續下去。此外，微生物群在營養食品和皮膚病治療等多種健康應用中的使用不斷增加，推動了人類微生物組市場的發展。技術創新，特別是次世代定序和先進的微生物表徵方法，進一步推動該領域的成長。總體而言，健康意識、人口變化和技術進步的交叉凸顯了人類微生物組市場顯著擴張的潛力。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東、非洲

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Seres Therapeutics, Inc.（US）
Ferring Pharmaceuticals（Switzerland）
Biomebank（Australia）
Nestle SA（Switzerland）
Sanofi（France）
Seed Health, Inc.（US）
Enterome（France）
Pendulum（US）
Quantbiome, Inc.（Dba Ombre）（US）
Vedanta Biosciences, Inc.（US）
Maat Pharma SA（France）
International Flavors & Fragrances, Inc.（US）
Optibiotx Health Plc（UK）
Synlogic, Inc.（US）
Guangzhou Zhiyi Biotechnology Co., Ltd.（China）
Aobiome（US）
Siolta Therapeutics（US）
Alveolus Bio, Inc.（US）
MRM Health NV（Belgium）
Biome Inc（US）
Sanzyme Biologics（India）
Biomx（Israel）
Nubiyota（US）
Quorum Innovations（US）

簡介目錄

Product Code: SQMIG35H2299

Global Human Microbiome Market size was valued at USD 0.8 Billion in 2022 and is poised to grow from USD 1.01 Billion in 2023 to USD 9.7 Billion by 2031, growing at a CAGR of 31.80% during the forecast period (2024-2031).

The human microbiome has emerged as a pivotal area of research, particularly due to its significant connections to respiratory and immune health. Studies have shown a correlation between gut microbiota composition-specifically populations of actinobacteria, firmicutes, and bacteroidetes-and respiratory issues, highlighting the critical role of microbiome health in overall immunity. For instance, advancements in microbiome therapies have been initiated to bolster immune response against emerging pathogens like SARS-CoV-2. Additionally, the pandemic has heightened awareness surrounding microbial diagnostics and chemistry, creating a robust market for microbiota research and applications. This trend is poised to continue in the post-pandemic landscape, fueled by an increasing prevalence of lifestyle-related diseases and an aging population, with projections estimating 69 million individuals aged 20-79 will have diabetes by 2045, according to the International Diabetes Association. Moreover, the human microbiome market is being propelled by the growing utilization of microbiota in diverse health applications, including dietary supplements and dermatological treatments. Technological innovations, particularly next-generation sequencing and advanced microbial characterization methods, are further facilitating growth within this sector. Overall, the intersection of health awareness, demographic shifts, and technological advancements underscores the potential for significant expansion in the human microbiome market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Human Microbiome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Human Microbiome Market Segmental Analysis

Global Human Microbiome Market is segmented by Product, Disease, Type, End User, and region. Based on Product, the market is segmented into Drugs, Probiotics, Prebiotics, and Synbiotics. Based on Disease, the market is segmented into Infectious Dieases, Gastrointestinal Diseases, Endocrine and Metabolic Disorders, and Other Diseases. Based on Type, the market is segmented into Bacterial Consortia Transplantation (BCT)/ Fecal Microbiotia Transplantation (FMT), Live Biotherapeutic Product, and Others. Based on End User, the market is segmented into Hospitals and Clinics, Long-Term Care Facilities, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Human Microbiome Market

The rising incidence of chronic diseases, including gastrointestinal disorders, obesity, and diabetes, significantly propels the Global Human Microbiome market. As scientific research increasingly elucidates the relationship between gut microbiota and these health issues, there is a burgeoning demand for microbiome-based treatments and interventions. This trend is fueling interest among both healthcare professionals and patients, resulting in heightened investments in research and development, as well as the commercialization of microbiome-related products. Consequently, this market is experiencing robust growth, as stakeholders recognize the potential of microbiome-targeted therapies to address pressing health challenges and improve patient outcomes.

Restraints in the Global Human Microbiome Market

A significant restraint in the Global Human Microbiome market is the exorbitant costs associated with research and development. The intricate nature of studying microbial communities and effectively translating these insights into viable therapies necessitates substantial financial and technical resources. Furthermore, the lengthy process of clinical trials, coupled with stringent regulatory approvals, adds layers of expense and complexity, which can hinder innovation and timely market entry of new products. As companies grapple with these financial constraints, the pace of advancements within the human microbiome sector may be slowed, limiting the potential growth and evolution of therapies aimed at leveraging this complex ecosystem.

Market Trends of the Global Human Microbiome Market

The Global Human Microbiome Market is witnessing a significant trend towards personalized medicine, driven by advancements in understanding the intricate relationship between microbial composition and individual health. As researchers and pharmaceutical companies increasingly focus on tailoring therapeutic interventions to specific microbial profiles, this approach results in more precise treatments and diagnostics for microbiota-related conditions. Not only does this trend enhance the efficacy of therapeutic agents, but it also fosters the development of innovative strategies to address diverse health issues. Consequently, the market is poised for growth as personalized microbiome-based solutions become integral to modern healthcare practices.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Technology Analysis
Patent Analysis
Regulatory Landscape

Human Microbiome Market by Product

Market Overview
Drugs
Probiotics
Prebiotics
Synbiotics

Human Microbiome Market by Disease

Market Overview
Infectious Diseases
Gastrointestinal Diseases
Endocrine & Metabolic Disorders
Other Diseases

Human Microbiome Market by Type

Market Overview
Bacterial Consortia Transplantation (BCT)/ Fecal Microbiotia Transplantation (FMT)
Live Biotherapeutic Product
Others

Human Microbiome Market by End User

Market Overview
Hospitals and Clinics
Long-Term Care Facilities
Other End Users

Human Microbiome Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Seres Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring Pharmaceuticals (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomebank (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nestle S.A. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seed Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Enterome (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pendulum (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quantbiome, Inc. (Dba Ombre) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vedanta Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Maat Pharma SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
International Flavors & Fragrances, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Optibiotx Health Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Synlogic, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guangzhou Zhiyi Biotechnology Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aobiome (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siolta Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alveolus Bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MRM Health NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biome Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanzyme Biologics (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomx (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nubiyota (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quorum Innovations (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments